NASDAQ:GRTS - Gritstone Oncology Stock Price, Forecast & News

Gritstone Oncology trades on the NASDAQ under the ticker symbol "GRTS."

Gritstone Oncology Inc (NASDAQ:GRTS) posted its earnings results on Tuesday, November, 12th. The company reported ($0.77) earnings per share (EPS) for the quarter, missing the Thomson Reuters' consensus estimate of ($0.66) by $0.11. The firm earned $0.98 million during the quarter, compared to analysts' expectations of $1.20 million. Gritstone Oncology had a negative return on equity of 54.23% and a negative net margin of 1,838.71%. View Gritstone Oncology's Earnings History.

Gritstone Oncology is scheduled to release their next quarterly earnings announcement on Thursday, March 26th 2020. View Earnings Estimates for Gritstone Oncology.

5 Wall Street analysts have issued 1 year price targets for Gritstone Oncology's shares. Their forecasts range from $17.00 to $20.00. On average, they expect Gritstone Oncology's stock price to reach $18.00 in the next twelve months. This suggests a possible upside of 73.2% from the stock's current price. View Analyst Price Targets for Gritstone Oncology.

5 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Gritstone Oncology in the last year. There are currently 5 buy ratings for the stock, resulting in a consensus recommendation of "Buy." View Analyst Ratings for Gritstone Oncology.

News coverage about GRTS stock has been trending extremely negative recently, InfoTrie Sentiment Analysis reports. The research firm scores the sentiment of press coverage by analyzing more than six thousand news and blog sources in real-time. The firm ranks coverage of public companies on a scale of negative five to five, with scores nearest to five being the most favorable. Gritstone Oncology earned a coverage optimism score of -4.2 on InfoTrie's scale. They also gave media headlines about the company a news buzz of 0.0 out of 10, indicating that recent press coverage is extremely unlikely to have an impact on the company's share price in the near future. View News Stories for Gritstone Oncology.

Gritstone Oncology saw a increase in short interest in January. As of January 31st, there was short interest totalling 3,410,000 shares, an increase of 14.0% from the January 15th total of 2,990,000 shares. Based on an average daily trading volume, of 173,200 shares, the days-to-cover ratio is presently 19.7 days. Currently, 17.5% of the company's shares are sold short. View Gritstone Oncology's Current Options Chain.

Some companies that are related to Gritstone Oncology include SpringWorks Therapeutics (SWTX), Beam Therapeutics (BEAM), Editas Medicine (EDIT), I-Mab (BDTX), Orchard Therapeutics (ORTX), NanoString Technologies (NSTG), BAVARIAN NORDIC/S (BVNRY), Krystal Biotech (KRYS), Adverum Biotechnologies (ADVM), Twist Bioscience (TWST), Mesoblast (MESO), Aerie Pharmaceuticals (AERI), Sangamo Therapeutics (SGMO), DBV TECHNOLOGIE/S (DBVT) and Vericel (VCEL).

Based on aggregate information from My MarketBeat watchlists, some companies that other Gritstone Oncology investors own include Clovis Oncology (CLVS), Crispr Therapeutics (CRSP), Sorrento Therapeutics (SRNE), AT&T (T), Agile Therapeutics (AGRX), Micron Technology (MU), Nektar Therapeutics (NKTR), Proteostasis Therapeutics (PTI), vTv Therapeutics (VTVT) and AbbVie (ABBV).

(GRTS) raised $85 million in an initial public offering on Friday, September 28th 2018. The company issued 6,100,000 shares at $13.00-$15.00 per share. Goldman Sachs, Cowen and Barclays acted as the underwriters for the IPO and BTIG was co-manager.

Gritstone Oncology's stock is owned by a variety of of retail and institutional investors. Top institutional shareholders include FMR LLC (15.00%), Casdin Capital LLC (6.03%), State Street Corp (1.31%), UBS Asset Management Americas Inc. (1.08%), Victory Capital Management Inc. (1.03%) and Victory Capital Management Inc. (1.02%). Company insiders that own Gritstone Oncology stock include Nicholas Simon and Raphael Rousseau. View Institutional Ownership Trends for Gritstone Oncology.

GRTS stock was sold by a variety of institutional investors in the last quarter, including Schroder Investment Management Group, Oxford Asset Management LLP, Victory Capital Management Inc., Victory Capital Management Inc., New York State Common Retirement Fund and UBS Asset Management Americas Inc.. View Insider Buying and Selling for Gritstone Oncology.

GRTS stock was acquired by a variety of institutional investors in the last quarter, including Casdin Capital LLC, Captrust Financial Advisors, State Street Corp, California Public Employees Retirement System, Geode Capital Management LLC, Goldman Sachs Group Inc., Barclays PLC and ProShare Advisors LLC. View Insider Buying and Selling for Gritstone Oncology.

Shares of GRTS can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity and Charles Schwab.

One share of GRTS stock can currently be purchased for approximately $10.39.

Gritstone Oncology has a market capitalization of $372.07 million and generates $1.19 million in revenue each year. The company earns $-64,780,000.00 in net income (profit) each year or ($7.26) on an earnings per share basis. Gritstone Oncology employs 113 workers across the globe.View Additional Information About Gritstone Oncology.

The official website for Gritstone Oncology is http://www.gritstoneoncology.com/.

Gritstone Oncology's mailing address is 5858 HORTON STREET SUITE 210, EMERYVILLE CA, 94608. The company can be reached via phone at 510-871-6100 or via email at [email protected]